BACKGROUND: Genetic predisposition to life-threatening cardiac arrhythmias such as congenital long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent treatable causes of sudden cardiac death in young adults and children. Recently, mutations in calmodulin (CALM1, CALM2) have been associated with severe forms of LQTS and CPVT, with life-threatening arrhythmias occurring very early in life. Additional mutation-positive cases are needed to discern genotype-phenotype correlations associated with calmodulin mutations. METHODS AND RESULTS: We used conventional and next-generation sequencing approaches, including exome analysis, in genotype-negative LQTS probands. We identified 5 novel de novo missense mutations in CALM2 in 3 subjects with LQTS (p.N98S, p.N98I, p.D134H) and 2 subjects with clinical features of both LQTS and CPVT (p.D132E, p.Q136P). Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1 to 9 years. Three of 5 probands had cardiac arrest and 1 of these subjects did not survive. The clinical severity among subjects in this series was generally less than that originally reported for CALM1 and CALM2 associated with recurrent cardiac arrest during infancy. Four of 5 probands responded to β-blocker therapy, whereas 1 subject with mutation p.Q136P died suddenly during exertion despite this treatment. Mutations affect conserved residues located within Ca(2+)-binding loops III (p.N98S, p.N98I) or IV (p.D132E, p.D134H, p.Q136P) and caused reduced Ca(2+)-binding affinity. CONCLUSIONS: CALM2 mutations can be associated with LQTS and with overlapping features of LQTS and CPVT.
BACKGROUND: Genetic predisposition to life-threatening cardiac arrhythmias such as congenital long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent treatable causes of sudden cardiac death in young adults and children. Recently, mutations in calmodulin (CALM1, CALM2) have been associated with severe forms of LQTS and CPVT, with life-threatening arrhythmias occurring very early in life. Additional mutation-positive cases are needed to discern genotype-phenotype correlations associated with calmodulin mutations. METHODS AND RESULTS: We used conventional and next-generation sequencing approaches, including exome analysis, in genotype-negative LQTS probands. We identified 5 novel de novo missense mutations in CALM2 in 3 subjects with LQTS (p.N98S, p.N98I, p.D134H) and 2 subjects with clinical features of both LQTS and CPVT (p.D132E, p.Q136P). Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1 to 9 years. Three of 5 probands had cardiac arrest and 1 of these subjects did not survive. The clinical severity among subjects in this series was generally less than that originally reported for CALM1 and CALM2 associated with recurrent cardiac arrest during infancy. Four of 5 probands responded to β-blocker therapy, whereas 1 subject with mutation p.Q136P died suddenly during exertion despite this treatment. Mutations affect conserved residues located within Ca(2+)-binding loops III (p.N98S, p.N98I) or IV (p.D132E, p.D134H, p.Q136P) and caused reduced Ca(2+)-binding affinity. CONCLUSIONS:CALM2 mutations can be associated with LQTS and with overlapping features of LQTS and CPVT.
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Wendy S VanScyoc; Brenda R Sorensen; Elena Rusinova; William R Laws; J B Alexander Ross; Madeline A Shea Journal: Biophys J Date: 2002-11 Impact factor: 4.033
Authors: L Zhang; K W Timothy; G M Vincent; M H Lehmann; J Fox; L C Giuli; J Shen; I Splawski; S G Priori; S J Compton; F Yanowitz; J Benhorin; A J Moss; P J Schwartz; J L Robinson; Q Wang; W Zareba; M T Keating; J A Towbin; C Napolitano; A Medina Journal: Circulation Date: 2000-12-05 Impact factor: 29.690
Authors: Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev Journal: Nat Methods Date: 2010-04 Impact factor: 28.547
Authors: M D Abou Ziki; S B Seidelmann; E Smith; G Atteya; Y Jiang; R G Fernandes; M A Marieb; J G Akar; A Mani Journal: Clin Genet Date: 2017-05-18 Impact factor: 4.438
Authors: Lia Crotti; Carla Spazzolini; David J Tester; Alice Ghidoni; Alban-Elouen Baruteau; Britt-Maria Beckmann; Elijah R Behr; Jeffrey S Bennett; Connie R Bezzina; Zahurul A Bhuiyan; Alpay Celiker; Marina Cerrone; Federica Dagradi; Gaetano M De Ferrari; Susan P Etheridge; Meena Fatah; Pablo Garcia-Pavia; Saleh Al-Ghamdi; Robert M Hamilton; Zuhair N Al-Hassnan; Minoru Horie; Juan Jimenez-Jaimez; Ronald J Kanter; Juan P Kaski; Maria-Christina Kotta; Najim Lahrouchi; Naomasa Makita; Gabrielle Norrish; Hans H Odland; Seiko Ohno; John Papagiannis; Gianfranco Parati; Nicole Sekarski; Kristian Tveten; Matteo Vatta; Gregory Webster; Arthur A M Wilde; Julianne Wojciak; Alfred L George; Michael J Ackerman; Peter J Schwartz Journal: Eur Heart J Date: 2019-09-14 Impact factor: 29.983
Authors: Liam Hovey; C Andrew Fowler; Ryan Mahling; Zesen Lin; Mark Stephen Miller; Dagan C Marx; Jesse B Yoder; Elaine H Kim; Kristin M Tefft; Brett C Waite; Michael D Feldkamp; Liping Yu; Madeline A Shea Journal: Biophys Chem Date: 2017-03-09 Impact factor: 2.352
Authors: Worawan B Limpitikul; Ivy E Dick; David J Tester; Nicole J Boczek; Pattraranee Limphong; Wanjun Yang; Myoung Hyun Choi; Jennifer Babich; Deborah DiSilvestre; Ronald J Kanter; Gordon F Tomaselli; Michael J Ackerman; David T Yue Journal: Circ Res Date: 2016-10-20 Impact factor: 17.367
Authors: Robert D Burgoyne; Nordine Helassa; Hannah V McCue; Lee P Haynes Journal: Cold Spring Harb Perspect Biol Date: 2019-05-01 Impact factor: 10.005